Tay-Sachs disease carrier screening: a model for prevention of genetic disease.
Tay-Sachs disease (TSD) is an autosomal-recessive, progressive, and ultimately fatal neurodegenerative disorder. Within the last 30 years, the discovery of the enzymatic basis of the disease, namely deficiency of the enzyme hexosaminidase A, made possible both enzymatic diagnosis of TSD and heterozygote identification. In the last decade, the cloning of the HEXA gene and the identification of more than 80 associated TSD-causing mutations has permitted molecular diagnosis in many instances. TSD was the first genetic condition for which community-based screening for carrier detection was implemented. As such, the TSD experience can be viewed as a prototypic effort for public education, carrier testing, and reproductive counseling for avoiding fatal childhood disease. More importantly, the outcome of TSD screening over the last 28 years offers convincing evidence that such an effort can dramatically reduce incidence of the disease.
Kaplan
F
F
McGill University-Montreal Children's Hospital Research Institute, Quebec, Canada. fkaplan@www.debelle.mcgill.ca
D000483:Alleles; D002170:Canada; D004252:DNA Mutational Analysis; D005006:Ethnicity / Q000235:genetics; D005260:Female; D005787:Gene Frequency; D006580:Genetic Carrier Screening; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D054818:Hexosaminidase A; D006801:Humans; D007585:Jews / Q000235:genetics*; D008297:Male; D017354:Point Mutation; D016742:Preconception Care; D011291:Premarital Examinations; D015397:Program Evaluation; D012306:Risk; D012680:Sensitivity and Specificity; D013661:Tay-Sachs Disease / Q000175:diagnosis* / Q000208:ethnology / Q000235:genetics / Q000517:prevention & control; D001619:beta-N-Acetylhexosaminidases / Q000032:analysis / Q000172:deficiency / Q000235:genetics
D054818:Hexosaminidase A; D001619:beta-N-Acetylhexosaminidases